The histone H3.3K36M mutation reprograms the epigenome of chondroblastomas

Science. 2016 Jun 10;352(6291):1344-8. doi: 10.1126/science.aae0065. Epub 2016 May 26.

Abstract

More than 90% of chondroblastomas contain a heterozygous mutation replacing lysine-36 with methionine-36 (K36M) in the histone H3 variant H3.3. Here we show that H3K36 methylation is reduced globally in human chondroblastomas and in chondrocytes harboring the same genetic mutation, due to inhibition of at least two H3K36 methyltransferases, MMSET and SETD2, by the H3.3K36M mutant proteins. Genes with altered expression as well as H3K36 di- and trimethylation in H3.3K36M cells are enriched in cancer pathways. In addition, H3.3K36M chondrocytes exhibit several hallmarks of cancer cells, including increased ability to form colonies, resistance to apoptosis, and defects in differentiation. Thus, H3.3K36M proteins reprogram the H3K36 methylation landscape and contribute to tumorigenesis, in part through altering the expression of cancer-associated genes.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acid Substitution
  • Bone Neoplasms / genetics*
  • Carcinogenesis / genetics*
  • Chondroblastoma / genetics*
  • Epigenesis, Genetic*
  • Genes, Neoplasm*
  • Histone-Lysine N-Methyltransferase / metabolism
  • Histones / genetics*
  • Humans
  • Lysine / genetics
  • Methylation
  • Mutation
  • Repressor Proteins / metabolism

Substances

  • Histones
  • Repressor Proteins
  • Histone-Lysine N-Methyltransferase
  • NSD2 protein, human
  • SETD2 protein, human
  • Lysine